1
|
Yang W, Wei Y, Wang T, Xu Y, Jin X, Qian H, Yang S, He S. Cytoplasmic localization of SETDB1‑induced Warburg effect via c‑MYC‑LDHA axis enhances migration and invasion in breast carcinoma. Int J Mol Med 2024; 53:40. [PMID: 38426579 PMCID: PMC10914311 DOI: 10.3892/ijmm.2024.5364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 01/31/2024] [Indexed: 03/02/2024] Open
Abstract
SET domain bifurcated 1 (SETDB1), a pivotal histone lysine methyltransferase, is transported to the cytoplasm via a chromosome region maintenance 1 (CMR1)‑dependent pathway, contributing to non‑histone methylation. However, the function and underlying mechanism of cytoplasmic SETDB1 in breast cancer remain elusive. In the present study, immunohistochemistry revealed that elevated cytoplasmic SETDB1 was correlated with lymph node metastasis and more aggressive breast cancer subtypes. Functionally, wound healing and Transwell assays showed that cytoplasmic SETDB1 is key for cell migration and invasion, as well as induction of epithelial‑mesenchymal transition (EMT), which was reversed by leptomycin B (LMB, a CMR1 inhibitor) treatment. Furthermore, RNA‑seq and metabolite detection revealed that cytoplasmic SETDB1 was associated with metabolism pathway and elevated levels of metabolites involved in the Warburg effect, including glucose, pyruvate, lactate and ATP. Immunoblotting and reverse transcription‑quantitative PCR verified that elevation of cytoplasmic SETDB1 contributed to elevation of c‑MYC expression and subsequent upregulation of lactate dehydrogenase A (LDHA) expression. Notably, gain‑ and loss‑of‑function approaches revealed that LDHA overexpression in T47D cells enhanced migration and invasion by inducing EMT, while its depletion in SETDB1‑overexpressing MCF7 cells reversed SETDB1‑induced migration and invasion, as well as the Warburg effect and EMT. In conclusion, subcellular localization of cytoplasmic SETDB1 may be a pivotal factor in breast cancer progression. The present study offers valuable insight into the novel functions and mechanisms of cytoplasmic SETDB1.
Collapse
Affiliation(s)
- Wenlin Yang
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| | - Yingze Wei
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| | - Ting Wang
- Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China
| | - Ying Xu
- Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China
| | - Xiaoxia Jin
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| | - Hongyan Qian
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| | - Shuyun Yang
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| | - Song He
- Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu 226006, P.R. China
| |
Collapse
|
2
|
Hu L, Cheng Z, Wu L, Luo L, Pan P, Li S, Jia Q, Yang N, Xu B. Histone methyltransferase SETDB1 promotes osteogenic differentiation in osteoporosis by activating OTX2-mediated BMP-Smad and Wnt/β-catenin pathways. Hum Cell 2023:10.1007/s13577-023-00902-w. [PMID: 37074626 DOI: 10.1007/s13577-023-00902-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/24/2023] [Indexed: 04/20/2023]
Abstract
Osteogenic differentiation plays important roles in the pathogenesis of osteoporosis. In this study, we explored the regulatory mechanism of histone methyltransferase SET domain bifurcated 1 (SETDB1) underlying the osteogenic differentiation in osteoporosis. The common osteoporosis-related genes were retrieved from the GeneCards, CTD, and Phenolyzer databases. The enrichment analysis was conducted on the candidate osteoporosis-related genes using the PANTHER software, and the binding site between transcription factors and target genes predicted by hTFtarget. The bioinformatics analyses suggested 6 osteoporosis-related chromatin/chromatin binding protein or regulatory proteins (HDAC4, SIRT1, SETDB1, MECP2, CHD7, and DKC1). Normal and osteoporosis tissues were collected from osteoporosis patients to examine the expression of SETDB1. It was found that SETDB1 was poorly expressed in osteoporotic femoral tissues, indicating that SETDB1 might be involved in the development of osteoporosis. We induced SETDB1 overexpression/knockdown, orthodenticle homeobox 2 (OTX2) overexpression, activation of Wnt/β-catenin or BMP-Smad pathways alone or in combination in osteoblasts or ovariectomized mice. The data indicated that SETDB1 methylation regulated H3K9me3 in the OTX2 promoter region and inhibited the expression of OTX2. Besides, the BMP-Smad and Wnt/β-catenin pathways were inhibited by OTX2, thereby resulting in inhibited osteogenic differentiation. Animal experiments showed that overexpressed SETDB1 could promote the increase of calcium level and differentiation of femoral tissues. In conclusion, upregulation of SETDB1 promotes osteogenic differentiation by inhibiting OTX2 and activating the BMP-Smad and Wnt/β-catenin pathways in osteoporosis.
Collapse
Affiliation(s)
- Lianying Hu
- Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China
- Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, People's Republic of China
| | - Zhen Cheng
- Clinical Laboratory, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, People's Republic of China
| | - Lunan Wu
- Department of Anesthesiology and Perioperative Medicine, The Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, The Second Hospital of Anhui Medical University, Hefei, 230601, People's Republic of China
| | - Liangliang Luo
- Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, People's Republic of China
| | - Ping Pan
- Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, People's Republic of China
| | - Shujin Li
- Clinical Laboratory, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, People's Republic of China
| | - Qiyu Jia
- Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, People's Republic of China.
| | - Ning Yang
- Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, Anhui Province, People's Republic of China.
| | - Bin Xu
- Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
| |
Collapse
|
3
|
Wu M, Fan B, Guo Q, Li Y, Chen R, Lv N, Diao Y, Luo Y. Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation. Biol Res 2018; 51:39. [PMID: 30309377 PMCID: PMC6180515 DOI: 10.1186/s40659-018-0189-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Accepted: 10/03/2018] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND SET domain bifurcated 1 (SETDB1) has been widely considered as an oncogene playing a critical role in many human cancers, including breast cancer. Nevertheless, the molecular mechanism by which SETDB1 regulates breast cancer tumorigenesis is still unknown. METHODS qRT-PCR assay or western blot analysis was performed to assess the expression level of SETDB1 mRNA or protein, respectively. siSETDB1, pCMV6-XL5-SETDB1, miR-381-3p mimic, or miR-381-3p inhibitor was transfected into cells to regulate the expression of SETDB1 or miR-381-3p. MiRNA directly interacted with SETDB1 was verified by luciferase reporter assay and RNA immunoprecipitation. CCK-8 assay, colony formation assay, flow cytometric analysis, and transwell assay were used to detect the abilities of cell proliferation, cell cycle progression and migration, respectively. Animal model of xenograft tumor was used to observe the regulatory effect of SETDB1 on tumor growth in vivo. RESULTS We verified that SETDB1 mRNA level was upregulated in breast cancer tissues and cell lines, and SETDB1 depletion led to a suppression of cell proliferation, cell cycle progression and migration in vitro, as well as tumor growth in vivo. SETDB1 was verified to be a target of miR-381-3p. Moreover, miR-381-3p overexpression suppressed cell proliferation, cell cycle progression and migration, whereas SETDB1 abated miR-381-3p-mediated regulatory function on breast cancer cells. CONCLUSIONS This study revealed that SETDB1 knockdown might suppress breast cancer progression at least partly by miR-381-3p-related regulation, providing a novel prospect in breast cancer therapy.
Collapse
Affiliation(s)
- Milu Wu
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Baohua Fan
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Qijing Guo
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Yan Li
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Rong Chen
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Nannan Lv
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Yinzhuo Diao
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| | - Yushuang Luo
- grid.459333.bDepartment of Oncology, The Affiliated Hospital of Qinghai University, No. 29, Tongren Rd, Xining, 810001 Qinghai China
| |
Collapse
|